Macquarie Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Macquarie Group’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-60,556	Closed	-$5.91M	–	1669
2015 Q1	$5.91M	Buy	60,556 +9,556	+19%	+$1.01M	0.01%	695
2014 Q4	$4.73M	Hold	51,000	–	–	0.01%	735
2014 Q3	$3.51M	Buy	51,000 +13,376	+36%	+$958K	0.01%	822
2014 Q2	$3.94M	Hold	37,624	–	–	0.01%	781
2014 Q1	$3.12M	Sell	37,624 -1,276	-3%	-$118K	0.01%	851
2013 Q4	$2.52M	Hold	38,900	–	–	﹤0.01%	905
2013 Q3	$2.46M	Buy	38,900 +8,829	+29%	+$435K	﹤0.01%	856
2013 Q2	$1.26M	Buy	+30,071	New	+$1.37M	﹤0.01%	1091

Macquarie Group's GEVA Position: Q2 2015 in Review

Macquarie Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 60,556 shares — an estimated $5.91M sold.

Macquarie Group first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $5.91M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Macquarie Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Macquarie Group sold 60,556 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $5.91M.
Macquarie Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
Macquarie Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $5.91M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Macquarie Group's 13F filing for Q2 2015, filed 14 Aug 2015.